Nektar rises 11% as BTIG initiates buy rating on autoimmune

BTIG has initiated Nektar Therapeutics (NASDAQ:NKTR) with a buy rating, citing the potential of rezpegaldesleukin, a potential first-in-class regulatory T cell stimulator, for autoimmune …

11%
OFF

Nektar Rises 11% As BTIG Initiates Buy Rating On Autoimmune

2 weeks from now

BTIG has initiated Nektar Therapeutics (NASDAQ:NKTR) with a buy rating, citing the potential of rezpegaldesleukin, a potential first-in-class regulatory T cell stimulator, for autoimmune …

msn.com

$4.00
OFF

Nektar Therapeutics (NASDAQ:NKTR) Stock Rating Upgraded By

2 weeks from now

Jan 9, 2025 · Finally, BTIG Research reissued a "buy" rating and issued a $4.00 target price on shares of Nektar Therapeutics in a research report on Monday, September 30th. Three …

marketbeat.com

$4.00
OFF

BTIG Upgrades Nektar Stock, Sees Upside On Rezpeg Potential

2 weeks from now

Sep 30, 2024 · BTIG has initiated coverage on shares of Nektar Therapeutics (NASDAQ: NASDAQ: NKTR) with a Buy rating and a price target set at $4.00.. The firm identified a …

investing.com

11%
OFF

Nektar Therapeutics (NKTR) Latest Stock News - Seeking Alpha

2 weeks from now

Dec 27, 2024 · Nektar rises 11% as BTIG initiates buy rating on autoimmune disorders asset SA News Mon, Sep. 30 3 Comments Nektar Therapeutics Non-GAAP EPS of -$0.19, revenue of …

seekingalpha.com

$4
OFF

Nektar Assumed With A Buy At BTIG - TipRanks.com

2 weeks from now

BTIG assumed coverage of Nektar with a Buy rating and $4 price target.There is a compelling disconnect between rezpegaldesleukin’s broad potential in I&I – Immunology & Inflammation – …

tipranks.com

400%
OFF

Eczema Drug Developer Nektar Gains Analyst Confidence With …

2 weeks from now

Nov 4, 2024 · Piper initiates with an Overweight rating and a price target of $7, an upside of over 400%. Price Action: NKTR stock is up 10.2% at $1.355 at last check Monday. Read Next:

yahoo.com

11%
OFF

Recent News For $NKTR | Nektar Therapeutics - SwingTradeBot

2 weeks from now

Aug 9, 2024 · Nektar rises 11% as BTIG initiates buy rating on autoimmune disorders asset: Sep 25: Nektar Therapeutics Announces Multiple Presentations for Rezpegaldesleukin at EADV …

swingtradebot.com

11%
OFF

Nektar Rises 11% As BTIG Initiates Buy Rating On - One News Page

2 weeks from now

Nektar rises 11% as BTIG initiates buy rating on autoimmune disorders asset • • Markets • One News Page: Monday, 30 September 2024. Skip to main content. One News Page. Trusted ...

onenewspage.com

11%
OFF

Nektar Announces Agreement To Sell Alabama Manufacturing …

2 weeks from now

More on Nektar Therapeutics Nektar sees promising phase 1 results of NKTR-255 in B-cell lymphoblastic leukemia Nektar rises 11% as BTIG initiates buy rating on autoimmune …

msn.com

$55
OFF

BTIG Initiates AnaptysBio With Buy And $55 Target PT, Cites …

2 weeks from now

Feb 26, 2024 · BTIG initiates AnaptysBio with buy and $55 target PT, cites autoimmune focus

investing.com

$55
OFF

BTIG Initiates AnaptysBio With Buy And $55 Target PT, Cites …

2 weeks from now

Feb 26, 2024 · On Monday, BTIG initiated coverage on biotechnology company AnaptysBio (NASDAQ: ANAB), which is listed on NASDAQ:ANAB, with a Buy rating and a price target set …

investing.com

$6.00
OFF

BTIG Initiates ImmunityBio Stock With Buy Rating, Cites Potential Of ...

2 weeks from now

6 days ago · On Friday, BTIG initiated coverage on ImmunityBio Inc (NASDAQ:IBRX) with a Buy rating and a price target of $6.00. The firm sees potential in the company's lead product, …

investing.com

FAQs about Nektar rises 11% as BTIG initiates buy rating on autoimmune Coupon?

Should you buy Nektar Therapeutics (NKTR)?

Nektar Therapeutics (NKTR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Julian Harrison from BTIG reiterated a Buy rating on the stock and has a $4.00 price target. ...

Why has Julian Harrison rated Nektar Therapeutics a buy?

Julian Harrison has given his Buy rating due to a combination of factors related to Nektar Therapeutics’ progress and strategic approach in their clinical trials. The company has recently completed enrollment in a Phase 2b trial for Rezpeg, targeting atopic dermatitis, with promising data expected by the second quarter of 2025. ...

What was Nektar Therapeutics' stock price on January 1st 2024?

Nektar Therapeutics' stock was trading at $0.5650 on January 1st, 2024. Since then, NKTR shares have increased by 141.0% and is now trading at $1.3615. How were Nektar Therapeutics' earnings last quarter? Nektar Therapeutics (NASDAQ:NKTR) announced its quarterly earnings results on Thursday, August, 8th. ...

Who is Nektar Therapeutics?

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. ...

What is the p/b ratio of Nektar Therapeutics?

Nektar Therapeutics has a P/B Ratio of 1.97. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. 3.40% of the float of Nektar Therapeutics has been sold short. Nektar Therapeutics has a short interest ratio ("days to cover") of 5.9. ...

Who are Nektar Therapeutics' top institutional shareholders?

Nektar Therapeutics' top institutional shareholders include Primecap Management Co. CA (3.21%), Connor Clark & Lunn Investment Management Ltd. (0.35%), GSA Capital Partners LLP (0.12%) and SG Americas Securities LLC (0.05%). ...